[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":89},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100604956","phase-1-study-of-syn818-with-olaparib-for-the-treatment-of-locally-advanced-or-metastatic-solid-tumors-100604956",false,"NCT07156253","Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors","A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SYN818 With Olaparib in Patients With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Having signed the written Informed Consent Form (ICF);\n* Male or female aged ≥18 years;\n* Life expectancy ≥12 weeks;\n* Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1;\n* Participant has a histologically confirmed diagnosis of advanced or metastatic solid tumor and has exhausted all standard-of-care treatment options, with documented BRCA mutations and\u002For homologous recombination repair deficiency (Part 1).\n* Participant has histologically or cytologically confirmed locally advanced or metastatic epithelial ovarian cancer or HER2-negative breast cancer, with documented BRCA mutations and\u002For homologous recombination repair deficiency (Part 2).\n* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;\n* No serious hematological, cardiopulmonary, or liver or kidney diseases other than the primary disease;\n* Adequate organ function and bone marrow function.\n\nExclusion Criteria:\n\n* Previous or current use of DNA Polymerase Theta (POLQ) inhibitors;\n* Current or previous other malignancy unless treated radically and with no evidence of recurrence or metastasis within the past 5 years;\n* Central nervous system (CNS) metastasis or meningeal metastasis with clinical symptoms, or other evidence indicating that CNS metastasis or meningeal metastasis has not been adequately controlled;\n* Patients with Myelodysplastic syndrome (MDS)\u002FAcute myeloid leukemia (AML) or with features suggestive of MDS\u002FAML;\n* Dysphagia or refractory nausea and vomiting, malabsorption, extracorporeal biliary shunts, or gastrointestinal disorders that affect drug absorption, e.g., Crohn's disease, ulcerative colitis, or short bowel syndrome, or other malabsorption conditions;\n* Treatment with an anti-cancer small molecule within 5 half-lives (t1\u002F2), or 2 weeks, whichever is shorter;\n* History of use within 2 weeks prior to the first dose of the study treatment and need to use protocol-prohibited potent inhibitors or potent inducers of cytochrome P450 (CYP) 3A4\u002FBCRP\u002FP-gp during the study;\n* Serious systemic diseases or laboratory abnormalities or other conditions that, at the Investigator's discretion, will make it unsuitable for the patient to participate in this clinical trial.","ALL","18 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors",[26,27,28,29,30],"Metastatic Solid Tumor","Ovarian Cancer","Breast Cancer","BRCA 1 \u002F2 and \u002F or HRD","Advanced Solid Tumors","RECRUITING","2025-08-27",{"date":34,"type":35},"2025-09-05","ACTUAL",{"date":37,"type":20},"2025-08-26",{"date":39,"type":20},"2029-02-25",{"name":41,"class":42},"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","INDUSTRY",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100599753","phase-1-study-of-syn608-for-the-treatment-of-advanced-or-metastatic-solid-tumors-100599753","NCT07088588","Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors","A First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SYN608, a Poly ADP-ribose Glycohydrolase (PARG) Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Having signed the written Informed Consent Form (ICF);\n* Male or female aged ≥18 years;\n* Life expectancy ≥12 weeks;\n* Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1;\n* Patients with histologically or cytologically confirmed locally advanced or metastatic breast cancer, ovarian cancer or other advanced solid tumors who have experienced disease progression, and available standard of care (SOC) therapies had been exhausted;\n* be willing to provide tumor tissue samples (fresh frozen \\[SF\\] or previously retained paraffin-embedded \\[FFPE\\] tumor tissue samples) or peripheral blood germline DNA or ctDNA sample to detect BRCA mutation, or other deficiency in the Homologous Recombination (HR) pathway (by the detection method of next generation sequencing \\[NGS\\])\n* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;\n* No serious hematological, cardiopulmonary, or liver or kidney diseases other than the primary disease;\n* Adequate organ function and bone marrow function.\n\nExclusion Criteria:\n\n* Previous or current use of Poly (ADP) ribose glycohydrolase (PARG) inhibitors;\n* Serious allergy to the study drug or any of its excipients;\n* Current or previous other malignancy unless treated radically and with no evidence of recurrence or metastasis within the past 5 years;\n* Central nervous system (CNS) metastasis or meningeal metastasis with clinical symptoms, or other evidence indicating that CNS metastasis or meningeal metastasis has not been adequately controlled;\n* Patients with Myelodysplastic syndrome (MDS)\u002FAcute myeloid leukemia (AML) or with features suggestive of MDS\u002FAML;\n* Dysphagia or refractory nausea and vomiting, malabsorption, extracorporeal biliary shunts, or gastrointestinal disorders that affect drug absorption, e.g., Crohn's disease, ulcerative colitis, or short bowel syndrome, or other malabsorption conditions;\n* Treatment with an anti-cancer small molecule within 5 half-lives (t1\u002F2), or 2 weeks, whichever is shorter;\n* History of use within 2 weeks prior to the first dose of the study treatment and need to use protocol-prohibited potent inhibitors or potent inducers of cytochrome P450 (CYP) 3A4\u002FBCRP\u002FP-gp during the study;\n* History of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease;\n* Serious systemic diseases or laboratory abnormalities or other conditions that, at the Investigator's discretion, will make it unsuitable for the patient to participate in this clinical trial.",{"count":52,"type":20},105,[23],"This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN608 as monotherapy in adult patients with advanced solid tumors",[56,26,27,28,57,58],"Advanced Solid Cancer","BRCA Mutation","HRR Deficiency","NOT_YET_RECRUITING","2025-07-25",{"date":62,"type":35},"2025-07-28",{"date":64,"type":20},"2025-07-31",{"date":66,"type":20},"2028-10-31",{"name":41,"class":42},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":43},"100567290","phase-1-study-of-syn818-for-the-treatment-of-advanced-or-metastatic-solid-tumors-100567290","NCT06666270","Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors","A First-in-human, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of SYN818, a DNA Polymerase Theta (POLQ) Inhibitor Alone in Patients With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Having signed the written Informed Consent Form (ICF);\n* Male or female aged ≥18 years;\n* Life expectancy ≥12 weeks;\n* Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1;\n* Patients with histologically or cytologically confirmed locally advanced or metastatic breast cancer, ovarian cancer, prostate cancer or other advanced solid tumors who have experienced disease progression, and available SOC therapies had been exhausted;\n* be willing to provide tumor tissue samples (fresh frozen \\[SF\\] or previously retained paraffin-embedded \\[FFPE\\] tumor tissue samples) or peripheral blood germline DNA or ctDNA sample to detect BRCA mutation, or other deficiency in the HR pathway (by the detection method of next generation sequencing \\[NGS\\])\n* At least one measurable lesion according to RECIST v1.1;\n* No serious hematological, cardiopulmonary, or liver or kidney diseases other than the primary disease;\n* Adequate organ function and bone marrow function.\n\nExclusion Criteria:\n\n* Previous or current use of POLQ inhibitors;\n* Hypersensitivity to the active pharmaceutical ingredient or any excipient of SYN818;\n* Central nervous system (CNS) metastasis or meningeal metastasis with clinical symptoms, or other evidence indicating that CNS metastasis or meningeal metastasis has not been adequately controlled;\n* Other malignant tumors than the study tumors within 5 years prior to the first dose of the study drug, except for localized cancers that have been evidently cured or disease-free for at least 3 years, such as basal or squamous cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, carcinoma in situ of cervix, or carcinoma in situ of breast;\n* Patients with Myelodysplastic syndrome (MDS)\u002FAcute myeloid leukemia (AML) or with features suggestive of MDS\u002FAML;\n* Dysphagia or refractory nausea and vomiting, malabsorption, extracorporeal biliary shunts, or gastrointestinal disorders that affect drug absorption, e.g., Crohn's disease, ulcerative colitis, or short bowel syndrome, or other malabsorption conditions;\n* Major surgery or serious trauma within 4 weeks prior to the first dose of the study treatment or major surgery planned during the trial period, and none of the AEs related to surgery or major trauma have resolved (to ≤ CTCAE v5.0 Grade 1 or baseline level) before the first dose of the study drug;\n* History of use within 2 weeks prior to the first dose of the study treatment and need to use protocol-prohibited potent inhibitors or potent inducers of cytochrome P450 (CYP) 3A4\u002FBCRP\u002FP-gp during the study;\n* Serious systemic diseases or laboratory abnormalities or other conditions that, at the Investigator's discretion, will make it unsuitable for the patient to participate in this clinical trial.",{"count":76,"type":20},30,[23],"This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors",[56,26,27,28,80,57,58],"Prostate Cancer","2025-07-18",{"date":83,"type":35},"2025-07-20",{"date":85,"type":35},"2024-11-21",{"date":87,"type":20},"2026-12-30",{"name":41,"class":42},""]